Table 2.
Breakpoints for carbapenems against Enterobacteriaceae family.
| Antibiotic | Guidelines | Disk Content (µg) | Disk Diffusion (mm) | Dilution (µg/mL) | ||||
|---|---|---|---|---|---|---|---|---|
| S | I | R | S | I | R | |||
| Ertapenem | EUCAST 1 CLSI 2 |
10 | ≥25 ≥23 |
- 19–21 |
≤25 ≤18 |
≤0.5 ≤0.5 |
- 1 |
0.5 ≥2 |
| Imipenem | EUCAST 1 CLSI 2 |
10 | 22 ≥23 |
21–18 20–22 |
≤17 ≤19 |
≤2 ≤1 |
3 2 |
4 ≥4 |
| Meropenem | EUCAST 1 CLSI 2 |
10 | 22 ≥23 |
21–17 20–22 |
16 ≤19 |
≤2 ≤1 |
3–7 2 |
8 ≥4 |
| Doripenem | EUCAST 3 CLSI 2 |
10 10 |
22 ≥23 |
21–17 20–22 |
≤16 ≤19 |
≤1 ≤1 |
2–3 2 |
4 ≥4 |
1 The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of minimum inhibitory concentrations (MICs) and zone diameters. Version 9.0, 2019. Available on: http//www.eucast.org [62]. 2 CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2019 [63]. 3 The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.1, 2018. Available on: http//www.eucast.org [64].